Rani Therapeutics Holdings, Inc. Class A Common Stock

Day range

$0.59 – $0.63

Open

$0.62

Prev close

$0.61

Volume

300.89K

Market cap

$69.94M

Shares out

115.42M

P/E

—

P/S

14.44

P/B

1.79

P/FCF

—

ROE

-76.8%

ROA

-49.5%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentAug 4, 2026

  On August 1, 2026, Michelle Gilson was appointed to the Board, effective immediately, until the earlier of the Company's next annual meeting of stockholders, the appointment and qualification of her successor, or her death, resignation, or removal. In addition, Ms. Gilson was appointed as chair of the Audit Committee. Michelle Gilson, age 34, has served as the Chief Financial Officer of Arcellx, Inc., a biotechnology company, from May 2022 through its acquisition by Gilead Sciences, Inc. in April 2026.

• Equity compensation grantJun 30, 2026

  Mr. Maestas will be granted a non-qualified option to purchase 2,000,000 shares of the Company's Class A common stock under the Company's 2026 Equity Inducement Plan (the "Inducement Plan"). The option will vest over a four-year period, with 25% of the shares subject to the option vesting on the one year anniversary of the date of his commencement of employment, and the remaining shares vesting equally over the following 36 months of continuous service.

• Annual meeting resultsMay 29, 2026

  On May 28, 2026, Rani Therapeutics Holdings, Inc. (the "Company") held its annual meeting of stockholders ("Annual Meeting"). The Company's stockholders elected the director nominees below, to hold office until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified, as follows: [voting results for 7 directors]. The Company's stockholders ratified the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Underwriting agreementMay 27, 2026

  Rani engaged H.C. Wainwright & Co., LLC to act as the lead placement agent and Chardan Capital Markets LLC as placement agent for the Offering and entered into engagement agreements dated May 10, 2026, as amended on May 25, 2026, and May 25, 2026, respectively, pursuant to which Rani has agreed to pay the placement agents a cash fee equal to 6.0% of the aggregate gross proceeds generated from the Offering.

• Quarterly earningsMay 15, 2026

  On May 15, 2026, Rani Therapeutics Holdings, Inc. (the "Company") issued a press release providing a corporate update, announcing its financial results for the three months ended March 31, 2026

Days to cover

11.6

Short interest

7.25M

Avg volume

624.09K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
  positiveGlobeNewswire Inc.· May 26, 2026
• Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
  positiveGlobeNewswire Inc.· Mar 25, 2026
• Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
  GlobeNewswire Inc.· Jun 24, 2024
• Rani Therapeutics to Participate in May Investor Conferences
  GlobeNewswire Inc.· May 14, 2024
• Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
  GlobeNewswire Inc.· May 9, 2024